$传奇生物(LEGN)$ $金斯瑞生物科技(01548)$ 

传奇55的目标价未包括对1-2线的估值， "Our PT ($55) is derived from a discounted cash flow analysis that assumes a 10% discount rate and 2% terminal growth value. We assume peak US market share of ~65% in late and third-line MM anti-BCMA CAR-T space."

关于Cartitude-4

国内券商研究进步很大，但与外资一线券商的差距还是肉眼可见。